Open Orphan PLC Jefferies 2019 London Healthcare Conference
November 15 2019 - 2:00AM
RNS Non-Regulatory
TIDMORPH
Open Orphan PLC
15 November 2019
15th November 2019
Open Orphan Plc
("Open Orphan" or the "Company")
Open Orphan to attend Jefferies 2019 London Healthcare
Conference
Open Orphan, a European-focussed, rare and orphan drug
consulting services platform, is pleased to announce that the
Company will be attending the Jefferies 2019 London Healthcare
Conference on 20(th) -21(st) November 2019 in London, UK.
The conference will be attended by a range of international
healthcare executives and institutional investors who will gather
to address near and long-term investment opportunities and to
discuss the mechanisms driving global healthcare.
Open Orphan's Chief Executive Officer, Cathal Friel, will be in
attendance and will be doing one-on-one meetings with attendees at
the conference.
Enquiries:
Open Orphan Plc Tel: +353 (0)1 6440007
Cathal Friel, Chief Executive Officer
Arden Partners (Nominated Adviser and Joint Broker) Tel: +44
(0)20 7614 5900
John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer
Davy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1
679 6363
Anthony Farrell (Corporate Finance)
Camarco (Financial PR) Tel: +44 (0)20 3757 4980
Tom Huddart / Billy Clegg / Daniel Sherwen
Notes to Editors:
Open Orphan plc is a European-focused, rare and orphan drug
consulting services platform. The Company intends to roll up a
number of orphan drug services businesses. Open Orphan has two data
driven digital platforms, a Genomic Health Data Platform, which is
establishing a rare disease database and a Virtual Rep platform
enabling pharmaceutical companies to engage key opinion leaders and
physicians. The Company is targeting rapid growth in one of the
fastest growing sectors in the global pharmaceutical industry
targeting under-supplied treatment for life threatening or very
serious diseases and rare disorders.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAGGGRPGUPBGMC
(END) Dow Jones Newswires
November 15, 2019 02:00 ET (07:00 GMT)
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Jul 2023 to Jul 2024